Search: onr:"swepub:oai:gup.ub.gu.se/240196" >
Recombinant Human E...
Recombinant Human Erythropoietin Improves Neurological Outcomes in Very Preterm Infants
-
Song, J. (author)
-
Sun, H. Q. (author)
-
Xu, F. L. (author)
-
show more...
-
Kang, W. Q. (author)
-
Gao, L. (author)
-
Guo, J. J. (author)
-
Zhang, Y. H. (author)
-
Xia, L. (author)
-
- Wang, Xiaoyang, 1965 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology
-
- Zhu, Changlian, 1964 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology
-
show less...
-
(creator_code:org_t)
- 2016-05-11
- 2016
- English.
-
In: Annals of Neurology. - : Wiley. - 0364-5134 .- 1531-8249. ; 80:1, s. 24-34
- Related links:
-
https://onlinelibrar...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Objective: To evaluate the efficacy and safety of repeated low-dose human recombinant erythropoietin (rhEPO) in the improvement of neurological outcomes in very preterm infants. Methods: A total of 800 infants of <= 32-week gestational age who had been in an intensive care unit within 72 hours after birth were included in the trial between January 2009 and June 2013. Preterm infants were randomly assigned to receive rhEPO (500IU/kg; n=366) or placebo (n=377) intravenously within 72 hours after birth and then once every other day for 2 weeks. The primary outcome was death or moderate to severe neurological disability assessed at 18 months of corrected age. Results: Death and moderate/severe neurological disability occurred in 91 of 338 very preterm infants (26.9%) in the placebo group and in 43 of 330 very preterm infants (13.0%) in the rhEPO treatment group (relative risk [RR]=0.40, 95% confidence interval [CI]=0.27-0.59, p < 0.001) at 18 months of corrected age. The rate of moderate/severe neurological disability in the rhEPO group (22 of 309, 7.1%) was significantly lower compared to the placebo group (57 of 304, 18.8%; RR=0.32, 95% CI=0.19-0.55, p < 0.001), and no excess adverse events were observed. Interpretation: Repeated low-dose rhEPO treatment reduced the risk of long-term neurological disability in very preterm infants with no obvious adverse effects.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Keyword
- birth-weight infants
- high-dose erythropoietin
- hypoxia-ischemia
- white-matter
- brain-injury
- retinopathy
- neuroprotection
- safety
- trial
- born
- Neurosciences & Neurology
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Song, J.
-
Sun, H. Q.
-
Xu, F. L.
-
Kang, W. Q.
-
Gao, L.
-
Guo, J. J.
-
show more...
-
Zhang, Y. H.
-
Xia, L.
-
Wang, Xiaoyang, ...
-
Zhu, Changlian, ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Neurosciences
- Articles in the publication
-
Annals of Neurol ...
- By the university
-
University of Gothenburg